SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Czechsinthemail who wrote (297)5/30/1998 3:50:00 AM
From: Jongmans  Respond to of 4474
 
Probably it will accelerate the research-process and in this way be cost-saving. In most cases you've to invest first to get higher productivity. Possibly a part of the expenses will be paid by the joint venture with Hoechst Marion Roussel.

In each case, Ariad has access to the newest research-technologies!!

Martin



To: Czechsinthemail who wrote (297)5/30/1998 3:27:00 PM
From: John Dwyer  Read Replies (1) | Respond to of 4474
 
I really don't think this a big deal for Ariad. I imagine that
their investment is probably not very large... the bulk of the
development expenses are no doubt being paid for by the other, deep-
pocketed, members. I really don't think there will be much
influence on ARIA. They already have a really good combichem
program so whatever comes out of the TRIDENT deal will only
serve to enhance what they have.

If I'm wrong, then I will share your concern


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News